Customize your search results with filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 09/18/2022

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 117 publications

Combination of modifying therapies in type 2 spinal muscular atrophy.

Summary: Combination of modifying therapies in type 2 spinal muscular atrophy.

Timing is everything: Clinical evidence supports pre-symptomatic treatment for spinal muscular atrophy.

Summary: Timing is everything: Clinical evidence supports pre-symptomatic treatment for spinal muscular atrophy.

Effects of ATLAS 2030 gait exoskeleton on strength and range of motion in children with spinal muscular atrophy II: a case series.

Summary: Effects of ATLAS 2030 gait exoskeleton on strength and range of motion in children with spinal muscular atrophy II: a case series.

Clinical follow-up analysis of nusinersen in the disease-modifying treatment of pediatric spinal muscular atrophy.

Summary: Clinical follow-up analysis of nusinersen in the disease-modifying treatment of pediatric spinal muscular atrophy.

Physical Therapy and Nusinersen Impact on Spinal Muscular Atrophy Rehabilitative Outcome.

Summary: Physical Therapy and Nusinersen Impact on Spinal Muscular Atrophy Rehabilitative Outcome.

Safety, tolerability, and efficacy of a widely available nusinersen program for Polish children with Spinal Muscular Atrophy.

Summary: Safety, tolerability, and efficacy of a widely available nusinersen program for Polish children with Spinal Muscular Atrophy.

Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial.

Summary: Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial.

Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial.

Summary: Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial.

An expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophy.

Summary: An expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophy.

Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: A systematic review of real-world study data.

Summary: Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: A systematic review of real-world study data.

Respiratory outcome of spinal muscular atrophy type 1 patients treated with nusinersen.

Summary: Respiratory outcome of spinal muscular atrophy type 1 patients treated with nusinersen.

Evaluation of real-life outcome data of patients with spinal muscular atrophy treated with nusinersen in Switzerland.

Summary: Evaluation of real-life outcome data of patients with spinal muscular atrophy treated with nusinersen in Switzerland.
Showing 1-12 of 117

Last Updated: 09/18/2022